Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
5 Years
6.9
55.79%
80%
—
119.06%
80%
—
5 Years
Score6.9
Net Growth55.79%
Net Trend80%
Net Income Consistency—
Rev Growth119.06%
Rev Trend80%
Revenue Consistency—
Cue Biopharma fundamental performance
Between 2020 and 2025, revenue grew from $ 3M to $ 27M and net income went from -$ 44M to -$ 26M. Revenue increased in 4 of those 5 years; net income in 4.
Cue Biopharma currently holds a 5-year HDB Score of 6.9 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 30.42 | — |
1 Year2025-08-12 | $ 23.70 | 28.35% |
5 Years2021-08-12 | $ 341.70 | -91.10% |
All Time2018-01-02 | $ 348.90 | -91.28% |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | All Time2018-01-02 |
|---|---|---|---|---|
| Price | $ 30.42 | $ 23.70 | $ 341.70 | $ 348.90 |
| Return | — | 28.35% | -91.10% | -91.28% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 32M | -$ 19M | $ 16M |
| 2025 | $ 27M | -$ 26M | $ 27M |
| 2024 | $ 9M | -$ 40M | $ 23M |
| 2023 | $ 5M | -$ 50M | $ 48M |
| 2022 | $ 1M | -$ 53M | $ 76M |
| 2021 | $ 14M | -$ 44M | $ 64M |
| 2020 | $ 3M | -$ 44M | $ 84M |
| 2019 | $ 3M | -$ 36M | $ 59M |
| IPO2018 | $ 1M | -$ 38M | $ 39M |
Explore beyond CUE
You're looking at Cue Biopharma. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
